Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution
Sign-up to one of our many Group Actions today - use our quick and easy form to start your claim for compensation.
Begin Your Group Action Claim Today
Sign-up to one of our many Group Actions today - use our quick and easy form to start your claim for compensation.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Bleo-Kyowa powder over a ‘minor’ defect being reported.
The agency cites glass particles being detected in a batch of the medicine back in April 2017.
Hospitals, pharmacies and other healthcare providers are requested to take caution in using the Bleomycin Sulphate powder that acts as an anticancer chemotherapy medicine.
The medicine is used for:
Only one batch is reportedly affected in the medical alert: 97B210.
The packets contain 10 doses and were first distributed in November 2017, and are due to expire on 31st August 2020. The marketing authorisation holder is conducting an investigation into the quality defect. New batches are reportedly unaffected and meet current quality requirements, and will therefore continue to be supplied to the U.K.
In the meantime, healthcare professionals are to take additional measures before using Bleo-Kyowa powders belonging to the alerted batch:
Glass particles in medicine of-course carry a very clear danger for patients. Sharp edges aside, it’s a foreign material that should not be inside our bloodstream at all. If the particulates are injected into the blood stream through the vein, they may be carried to the heart and then the lungs via the pulmonary arteries, causing damage.
For Group Action Claims we represent victims for, we can offer a Genuine No Win, No Fee agreement so you know you are safe to claim without the worry of having to pay thousands of pounds in legal bills if you can't win the case.
Learn more about No Win, No Fee
Start Your ClaimThe content of this post/page was considered accurate at the time of the original posting and/or at the time of any posted revision. The content of this page may, therefore, be out of date. The information contained within this page does not constitute legal advice. Any reliance you place on the information contained within this page is done so at your own risk.